Clinical trials: Vitiligo
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo.
- Trial name
- Tranquillo 2 (NCT06072183)
- Testing
- Ritlecitinib
- Where
- 229 sites in United States, Australia and 16 more
- Volunteers
- 1,571 people
- Sponsor
- Pfizer
Non-Segmental Vitiligo (NSV)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe…
- Trial name
- NCT07889492
- Testing
- EB06
- Where
- 4 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Edesa Biotech Inc.
Non-segmental Vitiligo
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into…
- Trial name
- VITESS (NCT07431177)
- Testing
- GIA632
- Where
- 83 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Vitiligo
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.
- Trial name
- NCT06625177
- Testing
- TEV-53408
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo.
- Trial name
- NCT06804811
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 78 sites in Argentina, Austria and 12 more
- Volunteers
- 250 people
- Sponsor
- Incyte Corporation
Vitiligo
Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo
The goal of this clinical trial is to learn if adding topical tacrolimus or topical tyrosine to narrowband UVB phototherapy works to treat vitiligo in adults. It will also learn about the safety of both combinations.
- Trial name
- NCT07532330
- Testing
- Narrowband UVB Phototherapy, Topical Tacrolimus 0.1% ointment, Topical Tyrosine 2% cream
- Where
- Egypt
- Volunteers
- 67 people
- Sponsor
- Minia University
Vitiligo, Non-Segmental Vitiligo (NSV)
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo.
- Trial name
- NCT07533019
- Testing
- LY4005130
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
NonSegmental Vitiligo
A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo
This Phase 3 study will evaluate the efficacy and safety of oral povorcitinib phosphate compared with placebo in Chinese adults with nonsegmental vitiligo who are considered suitable for systemic therapy.
- Trial name
- NCT07865312
- Testing
- Povorcitinib phosphate
- Where
- 44 sites in China
- Volunteers
- 174 people
- Sponsor
- Dermavon Holdings Limited
Nonsegmental Vitiligo
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin…
- Trial name
- NCT07108283
- Testing
- Zasocitinib
- Where
- 69 sites in United States, Canada and 7 more
- Volunteers
- 200 people
- Sponsor
- Takeda
Vitiligo
The Value of Methotrexate in NCES for Stable Vitiligo
The goal of this clinical trial is to learn if adding a six months course of Methotrexate would improve the results of non cultured epidermal suspension (NCES) in adult patients with acral and resistant vitiligo lesions over the…
- Trial name
- NCT07352293
- Testing
- Non cultured epidermal suspension
- Where
- Egypt
- Volunteers
- 21 people
- Sponsor
- Cairo University
Vitiligo
Assessment of Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet Dermoscopy
The goal of this observational study is to learn how different close-up skin imaging methods show vitiligo spots in adults with vitiligo.
- Trial name
- NCT07846969
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul Training and Research Hospital
Vitiligo
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo.
- Trial name
- Tranquillo LTE (NCT06163326)
- Testing
- Ritlecitinib, Ritlecitinib 100 mg
- Where
- 73 sites in United States, Australia and 11 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Non-segmental Vitiligo
Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo
This is a multicenter, randomized, double-blind, placebo-controlled, adaptive seamless design, Phase II/III study evaluating the efficacy and safety of FXS5626 in participants with non-segmental vitiligo.
- Trial name
- NCT07840820
- Testing
- Intervention1: FXS5626 Tablets, Intervention2: FXS5626 Tablets, Intervention3: FXS5626 Tablets
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Leukoderma, Hypopigmentation
Fractional CO2 Laser vs Dermabrasion With 5-Fluorouracil for Acquired Leukoderma
This randomized controlled prospective single-blinded comparative clinical study aims to compare the efficacy and safety of fractional carbon dioxide (CO2) laser therapy versus mechanical dermabrasion, both combined with topical…
- Trial name
- NCT07837908
- Testing
- Fractional CO2 Laser, Dermabrasion, 5-Fluorouracil
- Where
- Egypt
- Volunteers
- 16 people
- Sponsor
- Al-Azhar University
Non-Segmental Vitiligo
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
- Trial name
- NCT07828639
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Dermatologic Disease, Vitiligo
Vitiligo Registry for Adults and Children in the UK
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years…
- Trial name
- VIRTUAL-UK (NCT06218082)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Vitiligo
Topical Delgocitinib for Facial Vitiligo
This study is looking at a skin condition called vitiligo. Vitiligo is a skin condition where patches of the skin lose their natural color and become white. This study focuses specifically on vitiligo that affects the face.
- Trial name
- DelVito (NCT07820098)
- Testing
- Delgocitinib cream
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Lone Skov
NonSegmental Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
- Trial name
- TRuE-VIP1 (NCT06548360)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 98 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Incyte Corporation
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Non-Segmental Vitiligo (NSV)
Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
This study is a prospective, multicenter, real-world observational study to assess the clinical efficacy and safety of topical 1.5% Ruxolitinib phosphate cream used in combination with systemic corticosteroids in a real-world…
- Trial name
- NCT07673640
- Testing
- 1.5% Ruxolitinib Phosphate Cream (Opzelura), Corticosteroid Therapy
- Where
- 20 sites in China
- Volunteers
- 300 people
- Sponsor
- ShanShan Li